Strides Pharma Gains 12.07%: 5 Key Factors Driving the Week’s Rally

7 September: Strong Intraday Surge Amid Market Weakness

Strides Pharma began the week with a robust performance, surging 11.34% to close at Rs.1,178.40 on 7 September 2026. The stock reached an intraday high of Rs.1,147, marking an 8.38% rise from the previous close. This gain was remarkable given the Sensex declined 0.46% to 36,218.97 on the same day. The stock’s strength was underpinned by its trading above all major moving averages (5, 20, 50, 100, and 200 days), signalling a sustained bullish trend. This day marked the fourth consecutive gain for Strides Pharma, cumulatively up 11.44% over that period, highlighting strong buying interest despite a broadly negative market environment.

8 September: Valuation Upgrade Enhances Price Appeal

On 8 September, Strides Pharma’s valuation metrics improved notably, with its price-to-earnings (P/E) ratio at 18.82, significantly lower than peers such as Gland Pharma (42.77) and Emcure Pharma (35.36). The company’s enterprise value to EBITDA ratio stood at 13.24, reinforcing its attractive pricing relative to earnings. This valuation shift from very attractive to attractive reflected enhanced price appeal amid strong market performance. The stock closed at Rs.1,184.05, up 0.48%, while the Sensex declined 0.21%. The improved valuation was supported by solid returns on capital employed (15.54%) and equity (18.64%), underpinning efficient capital utilisation and profitability.

9 September: Upgrade to Buy Rating on Strong Fundamentals and Technicals

MarketsMOJO upgraded Strides Pharma’s Mojo Grade from Hold to Buy on 9 September, reflecting improvements in quality, valuation, financial trends, and technical indicators. The company reported its highest recent operating cash flow of ₹702.52 crores and a six-month high ROCE of 17.96%, signalling efficient capital use. The debt-equity ratio declined to 0.57 times, indicating reduced financial risk. Despite a modest average ROE of 9.60% and an increase in pledged promoter shares to 38.1%, the company’s consistent positive quarterly results and strong outperformance against the Sensex supported the upgrade. The stock closed at Rs.1,198.25, up 1.20%, while the Sensex fell 0.62%.

9 September: Bullish Momentum Confirmed by Technical Indicators

Alongside the rating upgrade, Strides Pharma’s technical outlook shifted from mildly bullish to bullish. Daily moving averages remained firmly positive, and the stock traded near its 52-week high of Rs.1,231.45. While weekly MACD was mildly bearish, the monthly MACD was bullish, indicating strong long-term momentum. Bollinger Bands on weekly and monthly charts were bullish, and On-Balance Volume (OBV) readings confirmed genuine buying interest. The stock’s relative strength was evident as it outperformed the Sensex by over 15% in the past week. This technical momentum shift reinforced investor confidence in the stock’s upward trajectory.

10 September: Technical Momentum Shifts to Mildly Bullish Amid Strong Returns

On 10 September, Strides Pharma’s technical momentum moderated slightly from bullish to mildly bullish. The stock closed at Rs.1,217.65, up 1.62%, approaching its 52-week high. Daily moving averages remained bullish, but weekly MACD stayed mildly bearish, and monthly RSI showed bearish tendencies, suggesting some medium-term caution. The Know Sure Thing (KST) oscillator was mildly bearish on weekly and monthly timeframes, while Bollinger Bands and OBV indicators remained bullish. Despite mixed signals, the stock’s strong returns continued to outpace the Sensex, which declined 0.03% that day. This nuanced technical picture suggests potential short-term consolidation amid a positive longer-term trend.

11 September: Profit Taking Leads to Slight Pullback

On the final trading day of the week, Strides Pharma experienced a correction, closing at Rs.1,186.10, down 2.59% from the previous close. The volume was relatively low at 11,792 shares, indicating subdued trading activity. The Sensex also declined 0.39% to 35,773.24. This pullback may reflect short-term profit taking after a strong rally earlier in the week. Despite this, the stock maintained a significant weekly gain of 12.07%, underscoring its resilience and relative strength compared to the broader market.

Key Takeaways

Positive Signals: Strides Pharma’s 12.07% weekly gain significantly outpaced the Sensex’s 1.68% decline, reflecting strong relative strength. The upgrade to a Buy rating by MarketsMOJO, supported by improved fundamentals such as high operating cash flow, efficient capital utilisation (ROCE 17.96%), and attractive valuation metrics (P/E ~19, EV/EBITDA ~13), underscores the company’s robust financial health. Technical indicators largely support a bullish trend, with daily moving averages and OBV confirming buying interest. The stock’s consistent outperformance over multiple time horizons highlights its resilience and growth potential within the pharmaceuticals sector.

Cautionary Signals: Despite the positive momentum, some technical indicators such as weekly MACD and monthly RSI show mild bearishness, suggesting potential short-term consolidation or volatility. The increase in pledged promoter shares to 38.1% and a modest ROE of 9.60% introduce risks that investors should monitor. The stock’s small-cap status may also entail higher volatility. The slight pullback on 11 September indicates profit taking, which could continue in the near term.

Conclusion

Strides Pharma Science Ltd demonstrated a compelling performance during the week of 7 to 11 September 2026, with a 12.07% price gain that outshone the broader market’s decline. The combination of a fundamental upgrade to a Buy rating, improved valuation attractiveness, and a shift to bullish technical momentum provides a strong foundation for the stock’s recent rally. While some caution is warranted due to mixed technical signals and promoter share pledging, the overall outlook remains positive. Investors tracking Strides Pharma should watch for confirmation of sustained earnings growth and monitor technical indicators as the stock approaches its 52-week high. The company’s consistent operational strength and valuation appeal continue to distinguish it within the Pharmaceuticals & Biotechnology sector.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today